TNFSF10 and prostate carcinoma: The results showed that the combined use of isoegomaketone and TRAIL inhibited the viability of TRAIL-resistant RC-58T/h/SA#4 primary malignant human prostate cancer cells by 80%, and their combined use showed little toxicity in normal RWPE-1 human prostate cells.